Beyond AlphaFold: AI Is Starting to Design New Biology

/in /by

AlphaFold transformed biology by predicting the three-dimensional structures of proteins. A new system called AlphaProtein Novo takes a very different step: instead of predicting proteins that already exist, it attempts to design entirely new enzymes with functions requested by researchers. The system uses machine learning to build both protein structure and amino-acid sequence around a […]

Read more

Gallic Acid Targets a New Prostate Cancer Progression Pathway

/in /by

A new preclinical study has identified the NF-κB/KLF7/L1CAM axis as a potential driver of prostate cancer progression and shown that gallic acid can interfere with this pathway. KLF7 was found to promote proliferation, migration and invasion by activating L1CAM, a protein associated with aggressive and metastatic behaviour. Upstream, phosphorylation of the NF-κB p65 subunit appeared […]

Read more

Phase 3 Trial for 177Lu-ludotadipep Radioligand Therapy for mCRPC

/in , , /by

A new phase 3 trial is testing 177Lu-ludotadipep (177Lu-FC705 or, simply, FC705), an experimental PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer (mCRPC). Unlike 177Lu-PSMA-617 (Pluvicto), ludotadipep includes an albumin-binding component designed to keep the radioligand in circulation longer and increase radiation delivery to PSMA-positive tumours. Earlier studies suggest that this strategy may allow substantial […]

Read more

Phase 2/3 Trial Will Test BAT Followed by Darolutamide

/in , , , /by

A newly registered randomised phase 2/3trial will test an unusual strategy in metastatic androgen pathway modulation-resistant prostate cancer (mAPMR; formerly mCRPC or castration-resistant prostate cancer): deliberately exposing resistant cancer cells to very high testosterone levels before attacking the androgen receptor again with darolutamide. The study plans to enrol 432 patients with mCRPC who have already […]

Read more

Phase 1/2 Trial: REGN21353 Plus Nezastomig STEAP1×CD3 and PSMA×CD28 Combination Enters mCRPC Trials

/in , , , /by

A new phase 1/2 trial will test REGN21353, a STEAP1×CD3 bispecific antibody, alone and in combination with nezastomig (REGN5678), a PSMA×CD28 costimulatory bispecific, in previously treated metastatic castration-resistant prostate cancer mCRPC (metastatic androgen pathway modulation-resistant prostate cancer mAPMR). The approach combines two different prostate cancer antigens and two complementary immune signals: CD3-mediated T-cell activation through […]

Read more

Decipher May Help Identify Who Really Needs ADT With Radiotherapy

/in /by

A new analysis from the randomised phase 3 NRG/RTOG 0815 trial suggests that the Decipher genomic classifier may do more than estimate prognosis: it may help predict which men with intermediate-risk prostate cancer actually benefit from adding short-term androgen deprivation therapy to dose-escalated radiotherapy. Researchers analysed tumour samples from 395 men, with a median follow-up […]

Read more

Phase 2 SOAR Trial: Treating Oligorecurrent Prostate Cancer Without ADT Shows Promise

/in , , /by

The phase II SOAR trial suggests that metastasis-directed therapy (MDT) alone may delay the need for androgen deprivation therapy in carefully selected men with PET-defined oligorecurrent prostate cancer. Twenty patients with up to ten nodal or bone metastases after radical prostatectomy received radiotherapy, salvage lymph-node dissection, or both, without concurrent ADT. At six months, 40% […]

Read more

Can AI Help Men Avoid ADT? The ASTuTE Trial is Testing That Question

/in , /by

A prospective clinical trial is testing whether artificial intelligence can help determine which men with intermediate-risk prostate cancer really need short-term androgen deprivation therapy alongside radiotherapy. The ASTuTE study uses the ArteraAI Prostate Test, which analyses digitised biopsy images together with clinical information to estimate both the risk of future metastasis and the likelihood that […]

Read more